Funds will support completion of feasibility testing, the launch of U.S. clinical studies and product development for the RESTORE™ Neuromuscular Interface System
Blue Arbor Technologies, Inc., a company developing novel neuromuscular interfaces and next-generation prosthetic control solutions for people with limb loss, today announced the close of its $10.5 million Series A financing round. The Series A was led by Blue Arbor’s strategic partner Ottobock, the global leader in prosthetics, neuro-orthotics, and wearable human bionics.
The financing will be used to fuel progress on the RESTORE™ Neuromuscular Interface System, a first-of-its kind platform that has the potential to fundamentally transform how people with limb loss control their prosthetic devices. Proceeds will be used to complete feasibility studies and to pursue FDA Investigational Device Exemption (IDE) to support clinical studies in the U.S. for the RESTORE™ ESU. In tandem, Blue Arbor will also begin development of the RESTORE™ ISU.
“Blue Arbor’s technology has the potential to set a new standard in prosthetic control,” said Oliver Jakobi, Chief Executive Officer of Ottobock. “This investment reflects our approach to deploying capital in areas that complement our core business and offer significant long-term growth potential. Together, we aim to translate pioneering research into scalable solutions that deliver meaningful value for people with limb loss.”
The RESTORE™ System is designed to enable independent and simultaneous control of the fingers, wrist, and elbow, unlocking levels of dexterity, speed, and reliability that approach natural limb movement and provide unparalleled control of tod